Novo Nordisk A/S (NYSE:NVO) Holdings Decreased by Auxano Advisors LLC

Auxano Advisors LLC decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 0.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,648 shares of the company’s stock after selling 180 shares during the quarter. Novo Nordisk A/S accounts for approximately 1.0% of Auxano Advisors LLC’s holdings, making the stock its 20th biggest position. Auxano Advisors LLC’s holdings in Novo Nordisk A/S were worth $3,067,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Pacific Center for Financial Services boosted its position in Novo Nordisk A/S by 100.0% during the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after purchasing an additional 135 shares during the last quarter. Copeland Capital Management LLC boosted its position in Novo Nordisk A/S by 100.0% during the third quarter. Copeland Capital Management LLC now owns 282 shares of the company’s stock valued at $26,000 after purchasing an additional 141 shares during the last quarter. Bell Investment Advisors Inc boosted its position in Novo Nordisk A/S by 79.9% during the third quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock valued at $26,000 after purchasing an additional 127 shares during the last quarter. CNB Bank acquired a new stake in Novo Nordisk A/S during the fourth quarter valued at $26,000. Finally, Citizens National Bank Trust Department boosted its position in Novo Nordisk A/S by 100.0% during the third quarter. Citizens National Bank Trust Department now owns 300 shares of the company’s stock valued at $27,000 after purchasing an additional 150 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO traded up $1.43 during trading hours on Tuesday, hitting $128.31. 7,593,161 shares of the company’s stock were exchanged, compared to its average volume of 4,799,729. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $138.28. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64. The stock has a market capitalization of $575.79 billion, a price-to-earnings ratio of 47.47, a PEG ratio of 2.12 and a beta of 0.41. The company’s 50-day moving average price is $126.92 and its 200-day moving average price is $112.40.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. The firm had revenue of $9.51 billion for the quarter, compared to analyst estimates of $9.14 billion. On average, sell-side analysts expect that Novo Nordisk A/S will post 3.32 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Investors of record on Monday, March 25th were paid a dividend of $0.664 per share. This represents a yield of 0.9%. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date of this dividend was Friday, March 22nd. Novo Nordisk A/S’s payout ratio is currently 49.17%.

Analyst Ratings Changes

NVO has been the subject of a number of research reports. Morgan Stanley initiated coverage on Novo Nordisk A/S in a research report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price objective for the company. UBS Group initiated coverage on Novo Nordisk A/S in a research report on Tuesday, January 16th. They issued a “neutral” rating for the company. BMO Capital Markets initiated coverage on Novo Nordisk A/S in a research report on Friday, April 12th. They issued an “outperform” rating and a $163.00 price target for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Thursday, April 18th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $133.60.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.